Last reviewed · How we verify
Nevirapine and mulitvitamins
Nevirapine and mulitvitamins is a non-nucleoside reverse transcriptase inhibitor Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV. Also known as: Viramune® (Boehringer Ingelheim).
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of the HIV virus.
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of the HIV virus. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | Nevirapine and mulitvitamins |
|---|---|
| Also known as | Viramune® (Boehringer Ingelheim) |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | non-nucleoside reverse transcriptase inhibitor |
| Target | reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Nevirapine specifically binds to the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA. This action inhibits the replication of the virus, thereby reducing the viral load in the body. Nevirapine is often used in combination with other antiretroviral medications to treat HIV-1 infection.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of mother-to-child transmission of HIV
Common side effects
- Rash
- Nausea
- Fatigue
- Headache
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nevirapine and mulitvitamins CI brief — competitive landscape report
- Nevirapine and mulitvitamins updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Nevirapine and mulitvitamins
What is Nevirapine and mulitvitamins?
How does Nevirapine and mulitvitamins work?
What is Nevirapine and mulitvitamins used for?
Who makes Nevirapine and mulitvitamins?
Is Nevirapine and mulitvitamins also known as anything else?
What drug class is Nevirapine and mulitvitamins in?
What development phase is Nevirapine and mulitvitamins in?
What are the side effects of Nevirapine and mulitvitamins?
What does Nevirapine and mulitvitamins target?
Related
- Drug class: All non-nucleoside reverse transcriptase inhibitor drugs
- Target: All drugs targeting reverse transcriptase
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Treatment of HIV-1 infection in adults and children
- Indication: Drugs for Prevention of mother-to-child transmission of HIV
- Also known as: Viramune® (Boehringer Ingelheim)